T. Rowe Price Investment Management Reports 8.2% Position In Xenon Without Seeking Control

The investment manager reported 7,905,757 shares, with sole voting authority covering 7,558,551 shares.

Share
T. Rowe Price Investment Management Reports 8.2% Position In Xenon Without Seeking Control

T. Rowe Price Investment Management reported an 8.2% position in Xenon Pharmaceuticals, which develops drugs for neurological and psychiatric disorders, in a passive ownership disclosure filed Friday. The manager certified that the shares were held for ordinary business purposes, rather than to change or influence Xenon’s control.

7.9 Million Shares, Different Voting Authority

The reported position covers 7,905,757 common shares on the SEC disclosure’s beneficial-ownership basis. The ownership figures are dated September 30, 2026; Friday is the filing date, not the date of a reported purchase.

T. Rowe Price Investment Management reported sole voting authority for 7,558,551 shares. Its sole authority to dispose of shares covers the full 7,905,757-share position, with no shared voting or disposal authority reported.

The control certification applies to both the purpose and effect of holding the securities. The manager also certified that the position was not connected to participation in a transaction aimed at changing or influencing control, apart from the certification’s exception for specified director-nomination activities.

Azetukalner Leads Xenon’s Drug Pipeline

Xenon’s main investigational medicine, azetukalner, is undergoing late-stage studies for epilepsy, major depressive disorder and bipolar depression. Its earlier-stage work includes potential medicines for pain and Dravet syndrome, a form of epilepsy.

The company also licenses drug-development rights to Neurocrine Biosciences through a collaboration carrying milestone payments and royalties. Xenon received a $7.5 million milestone payment in February 2025.

Xenon’s market value was $3.6 billion in Friday trading as of 11:07 a.m. ET.

The reported position gives T. Rowe Price Investment Management voting authority over 7,558,551 Xenon shares; the manager’s certification places that authority outside a control-seeking purpose.

Sources